2020 Legislative Update: Week 9
Week 9 of Georgia’s legislative session was both busy and filled with uncertainty as the General Assembly looked to navigate not only crossover day but also how to proceed in light of CoviD-19. Crossover day is the last day a bill may crossover from its originating chamber and so if a bill does not crossover it is no longer viable that session though its contents may be subsequently added to a viable bill. Crossover day was March 12 and the General Assembly worked deep into the night to get bills out of their originating chambers.
For GPhA, several key bills had already crossed over which made crossover day somewhat less stressful. Those bills are:
- SB 313 (Sen. Burke’s PBM bill)
- HB 918 (Rep. Cooper’s update to the Pharmacy Anti-Steering Act and Pharmacy Audit Bill of Rights)
- HB 946 (Rep. Knight’s PBM bill & companion to SB 313)
- HB 947 (Rep. Knight’s bill seeking a study of the fiscal impact of carving Rx benefits from Medicaid managed care & mandating a carve out if the study reflects potential annual savings of $20 million or more)
- HB 991 (Rep. Hatchett’s legislation creating the Healthcare Transparency and Accountability Oversight Committee)
In addition, several other bills GPhA is monitoring made crossover while others did not. Set forth below is a breakdown of those bills.
Last week the General Assembly made the decision to suspend the legislative session until further notice due to CoviD-19 concerns. The session will reconvene, and the hope is that when it does the body will continue to work on moving legislation forward in the remaining days of the session. The General Assembly also passed the midyear budget via HB 792 which, amongst other things, contained $175,000 for DCH to conduct an actuarial study on the fiscal impact of carving Rx benefits from Medicaid managed care. In a year with much belt tightening and several distracting factors, getting this money appropriated is a significant step forward for assessing the potential savings the state may achieve via a Medicaid managed care Rx carve out and for transparency.
GPhA monitored bills that made crossover
- HB 759 (drug update)
- HB 791 (authorizing conversion of maintenance meds from 30 days to 90 days)
- HB 847 (hemp farming)
- HB 888 (surprise billing)
- SB 28 (now dealing with reasonableness of copays)
- SB 272 (OTC cough syrup restrictions)
- SB 311 (restricting remuneration in connection with referral to/from substance abuse providers)
- SB 532 (online provider directories)
- SB 359 (surprise billing)
- SB 372 (amongst other things, increasing availability of naloxone via distributors)
- SB 391 (requiring coverage for medications dispensed during declared emergencies)
GPhA monitored bills that did not make crossover
- HB 813 (Medicaid expansion)
- HB 864 (excise tax on vape devices and products)
- HB 952 (restricting corporate practice of pharmacy)
- HB 961 (transparency for prescription drugs which state expends significant funds)
- HB 1027 (Dealing with PBM treatment of rebates)
- HB 1105 (patient protection through health information)
- HB 1128 (PBM reform – introduced the week of crossover)
- SB 376 (insulin costs)
- SB 415 (tort reform)
- SB 427 (Rx carve out from Medicaid managed care – companion to HB 947 which did make cross over)
- SB 433 (drug pricing transparency)
- SB 481 (exempting low THC and marijuana products approved by FDA from certain definitions)